Image Name - Referrals for Clinicians

How We Work With Healthcare Providers

How We Work With Healthcare Providers

In our experience, patients are best served when the all members of the provider team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral
Image Name - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • Spravato (intranasal Ketamine)
  • Stellate Ganglion Blocks (SGB)
  • IV Nutrients & Vitamins
  • IV NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)
  • Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

Magnesium And Ketamine In The Treatment Of Depression

January 6, 2019

Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus.

Read More

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

October 3, 2018

Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge, Bettina B. Hoeppner, Cristina Cusin, Dawn […] Read More

How healthy is the healthspan concept?

August 6, 2018

The concept of healthspan is relatively new in geroscience research, which seeks to understand the biological mechanisms of aging

Read More

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain

July 1, 2018

Steven P. Cohen, MD; Anuj Bhatia, MBBS, MD; Asokumar Buvanendran, MD; Eric S. Schwenk, MD; […] Read More

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

April 17, 2018

Carola Rong, Caroline Park, Joshua D. Rosenblat, Mehala Subramaniapillai, Hannah Zuckerman, Dominika Fus, Yena L. […] Read More

Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders

March 21, 2018

Paul Glue, Shona M Neehoff, Natalie J Medlicott, Andrew Gray, Guy Kibby, Neil McNaughton First […] Read More

depression, man, anxiety

Ketamine for Social Anxiety Disorder

January 21, 2018

Ketamine is a potent N-methyl-d-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial

Read More

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis

October 3, 2017

Samuel T. Wilkinson, M.D., Elizabeth D. Ballard, Ph.D., Michael H. Bloch, M.D., M.S., Sanjay J. […] Read More

Scroll to Top